{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:22Z","timestamp":1790692222573,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022754","name":"Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020625","name":"Saveetha Institute of Medical and Technical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijbiomac.2026.150512","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:10:01Z","timestamp":1769271001000},"page":"150512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy"],"prefix":"10.1016","volume":"344","author":[{"given":"H. Thamarai","family":"Kannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieshita","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.150512_bb0005","doi-asserted-by":"crossref","DOI":"10.1159\/000541077","article-title":"The impact of normal hepatobiliary cell zonation programs on the phenotypes and functions of primary liver tumors","author":"Aoki","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0015","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.3748\/wjg.v24.i39.4436","article-title":"Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer","volume":"24","author":"O\u2019Rourke","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0020","first-page":"187","article-title":"From liver fibrosis to hepatocarcinogenesis: role of excessive liver H2O2 and targeting nanotherapeutics","volume":"23","author":"Shao","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0025","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2811286","article-title":"Insights into the role of oxidative stress in hepatocellular carcinoma development","volume":"28","author":"Li","year":"2023","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1188\/08.CJON.759-766","article-title":"Symptom management in hepatocellular carcinoma","volume":"12","author":"Sun","year":"2008","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1479-5876-9-171","article-title":"Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview","volume":"9","author":"Marra","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12672-025-01747-5","article-title":"Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0050","article-title":"Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0306-9877(02)00223-2","article-title":"Mitochondrial 16S rRNA gene encodes a functional peptide, a potential drug for Alzheimer\u2019s disease and target for cancer therapy","volume":"59","author":"Maximov","year":"2002","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10989-023-10558-7","article-title":"A review on mitochondrial derived peptide Humanin and small humanin-like peptides and their therapeutic strategies","volume":"29","author":"Thamarai Kannan","year":"2023","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1492215","article-title":"Nanomaterial-based cancer immunotherapy: enhancing treatment strategies","volume":"12","author":"Tian","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12935-022-02843-0","article-title":"Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination","volume":"23","author":"Gromowski","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0075","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/hep.32007","article-title":"Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States","volume":"74","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0080","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.3390\/ijms25168641","article-title":"Fibrosis and hepatocarcinogenesis: role of gene-environment interactions in liver disease progression","volume":"25","author":"Banerjee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s44276-024-00050-0","article-title":"Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management","volume":"2","author":"Johnson","year":"2024","journal-title":"BJC Rep."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13578-020-00488-y","article-title":"Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0095","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cam4.1998","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014meta-analytic assessment","volume":"8","author":"Tarao","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0100","doi-asserted-by":"crossref","first-page":"000","DOI":"10.14218\/JCTH.2023.00189","article-title":"Update on the diagnosis and treatment of combined hepatocellular cholangiocarcinoma","volume":"000","author":"Chu","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04172-9","article-title":"Comprehensive molecular profiling of combined hepatocellular carcinoma and cholangiocarcinoma reveals distinct notch signaling subgroups with prognostic significance","author":"Yang","year":"2025","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000541077","article-title":"The impact of normal hepatobiliary cell zonation programs on the phenotypes and functions of primary liver tumors","author":"Aoki","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0115","article-title":"Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0120","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.3390\/jcm12237469","article-title":"The complexity of the tumor microenvironment in hepatocellular carcinoma and emerging therapeutic developments","volume":"12","author":"Argentiero","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0125","series-title":"Handbook of Oxidative Stress in Cancer: Mechanistic Aspects","first-page":"1","article-title":"Oxidative stress in Hepatocarcinogenesis and role of antioxidant therapy","author":"El Sayed","year":"2021"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109699","article-title":"ROS in hepatocellular carcinoma: what we know","volume":"744","author":"Xing","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0135","article-title":"Antioxidative stress: inhibiting reactive oxygen species production as a cause of radioresistance and chemoresistance","volume":"2021","author":"Chen","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antiox13010028","article-title":"Oxidative stress and redox-dependent pathways in cholangiocarcinoma","volume":"13","author":"Caligiuri","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-019-03667-9","article-title":"ROS and diseases: role in metabolism and energy supply","volume":"467","author":"Yang","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0155","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0160","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1535-7163.MCT-12-0093","article-title":"Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo","volume":"11","author":"Coriat","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104361","article-title":"The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma","volume":"197","author":"Cai","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0170","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.7150\/thno.32462","article-title":"ZnAs@SiO 2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1\/JAK2\/STAT3 signaling","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12935-019-0898-7","article-title":"YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway","volume":"19","author":"Zhou","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0180","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/pharmaceutics13101631","article-title":"Bi-functional peptides as a new therapeutic tool for hepatocellular carcinoma","volume":"13","author":"Savier","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104381","article-title":"MOTS-c inhibits osteolysis in the mouse calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation","volume":"147","author":"Yan","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fnmol.2025.1553308","article-title":"SHLP6: a novel NLRP3 and Cav1 modulating agent in cu-induced oxidative stress and neurodegeneration","volume":"18","author":"Thamarai Kannan","year":"2025","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1478-3231.2007.01637.x","article-title":"Molecular pathogenesis of hepatocellular carcinoma","volume":"28","author":"Wong","year":"2008","journal-title":"Liver Int."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0200","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00432-021-03826-w","article-title":"Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications","volume":"148","author":"Raja","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.gendis.2023.02.050","article-title":"WNT\/\u03b2-catenin signaling in hepatocellular carcinoma: the aberrant activation, pathogenic roles, and therapeutic opportunities","volume":"11","author":"Gajos-Michniewicz","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01188.x","article-title":"Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells","volume":"82","author":"Minke","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0220","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nature756","article-title":"Kremen proteins are Dickkopf receptors that regulate Wnt\/\u03b2-catenin signalling","volume":"417","author":"Mao","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0225","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-025-07789-5","article-title":"Inhibition of Wnt\/\u03b2-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma","volume":"16","author":"He","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0230","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2012.05.048","article-title":"\u03b2-Catenin regulates hepatic mitochondrial function and energy balance in mice","volume":"143","author":"Lehwald","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0240","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","article-title":"Immunotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"29","author":"Mandlik","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163291","article-title":"Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models","volume":"133","author":"Lu","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/cancers13020271","article-title":"Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials","volume":"13","author":"Rochigneux","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0255","first-page":"31","article-title":"The evolving role of PD-L1 inhibition in non-small cell lung Cancer: a review of Durvalumab and Avelumab., Cancer","volume":"5","author":"Neumann","year":"2022","journal-title":"Medizinhist. J."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s11658-024-00637-y","article-title":"Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1\/SOX10 regulatory axis","volume":"29","author":"Martinkova","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00562","article-title":"Editorial: emerging concepts on the NKG2D receptor-ligand Axis in health and diseases","volume":"11","author":"Guerra","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0270","article-title":"Bispecific c-met\/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0280","article-title":"Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0285","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0290","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0295","article-title":"CAR-T cell therapy: advances in digestive system malignant tumors., molecular therapy","volume":"32","author":"Xu","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0300","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0305","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS624","article-title":"A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC)","volume":"41","author":"Xie","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0315","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0320","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3390\/cancers12103025","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives","volume":"12","author":"Federico","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0325","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0330","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of Tremelimumab plus Durvalumab for patients with Unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-10-16","article-title":"Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin","volume":"10","author":"Wei","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0340","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.2147\/OTT.S156844","article-title":"Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona clinic liver Cancer stage C: a meta-analysis of Asian population","volume":"11","author":"Ni","year":"2018","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0345","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1158\/1078-0432.CCR-11-2322","article-title":"Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib","volume":"18","author":"Lachenmayer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0350","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.3390\/cancers14225525","article-title":"Lenvatinib as first-line treatment for Unresectable hepatocellular carcinoma: a systematic review and Meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102179","article-title":"Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"63","author":"Kulkarni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0360","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","article-title":"FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma","volume":"30","author":"Patel","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0365","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","article-title":"Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial","volume":"30","author":"Kim","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0370","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0375","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of Ramucirumab (IMC-1121B), a fully human immunoglobulin G 1 monoclonal antibody targeting the vascular endothelial growth factor Receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0380","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10637-024-01441-3","article-title":"Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (the R-evolution study)","volume":"42","author":"Kobayashi","year":"2024","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0385","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s10238-023-01014-3","article-title":"Therapeutic options in hepatocellular carcinoma: a comprehensive review","volume":"23","author":"Suresh","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0390","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0395","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2147\/JHC.S365002","article-title":"Systemic therapy in advanced hepatocellular carcinoma: patient selection and key considerations","volume":"9","author":"Storandt","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0400","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0405","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0410","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21037\/hbsn-22-143","article-title":"Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0415","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jfma.2022.03.017","article-title":"Immune checkpoint inhibitors for hepatocellular carcinoma \u2013 a game changer in treatment landscape","volume":"121","author":"Liu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0420","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00425-014-2123-1","article-title":"Identification of small secreted peptides (SSPs) in maize and expression analysis of partial SSP genes in reproductive tissues","volume":"240","author":"Li","year":"2014","journal-title":"Planta"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0425","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biom8010004","article-title":"Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo","volume":"8","author":"Kumar","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0430","first-page":"380","article-title":"Anticancer peptides and proteins: a panoramic view","volume":"20","author":"Liberio","year":"2013","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0435","first-page":"5","article-title":"Bioactive peptides for anticancer therapies","volume":"4","author":"Zhang","year":"2023","journal-title":"Biomater. Transl."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109724","article-title":"Peptide-based strategies for overcoming multidrug-resistance in cancer therapy","volume":"36","author":"Luo","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0445","article-title":"SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment","volume":"9","author":"Xie","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0450","series-title":"Cancer Stem Cells and Signaling Pathways","first-page":"581","article-title":"An overview of hepatocellular carcinoma stem cells and potential targeted therapies","author":"Zaky","year":"2024"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114257","article-title":"Natural peptides for immunological regulation in cancer therapy: mechanism, facts and perspectives","volume":"159","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0460","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.3390\/molecules25122850","article-title":"Antimicrobial peptides as anticancer agents: functional properties and biological activities","volume":"25","author":"Tornesello","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0465","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.18632\/oncotarget.21148","article-title":"Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma","volume":"8","author":"Barbhuiya","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0470","doi-asserted-by":"crossref","DOI":"10.4172\/2153-2435.1000183","article-title":"In vitro cytotoxicity of native and Rec-Pediocin CP2 against cancer cell lines: a comparative study","volume":"03","author":"Kumar","year":"2012","journal-title":"Pharm. Anal. Acta"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0475","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2174\/15680096113139990081","article-title":"&#946;-catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid","volume":"13","author":"Delgado","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0480","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cell.2016.02.004","article-title":"Engineering cellular metabolism","volume":"164","author":"Nielsen","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0485","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor Lenvatinib (E7080) in advanced medullary thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0490","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1073\/pnas.0704301104","article-title":"Fluctuations in density of an outbreak species drive diversity cascades in food webs","volume":"104","author":"Eveleigh","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.peptides.2015.06.006","article-title":"High fat diet impairs the function of glucagon-like peptide-1 producing L-cells","volume":"77","author":"Richards","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.lwt.2021.111402","article-title":"Characterization of flavor frame in shiitake mushrooms (Lentinula edodes) detected by HS-GC-IMS coupled with electronic tongue and sensory analysis: influence of drying techniques","volume":"146","author":"Hou","year":"2021","journal-title":"LWT"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0505","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccell.2012.07.005","article-title":"A review of influenza","volume":"24","author":"Dambaugh","year":"2012","journal-title":"Crit. Care Nurs. Clin. North Am."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0510","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tips.2012.03.006","article-title":"Structural biology and drug discovery for protein\u2013protein interactions","volume":"33","author":"Jubb","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0515","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tips.2021.11.008","article-title":"Targeting intracellular protein\u2013protein interactions with macrocyclic peptides","volume":"43","author":"Buyanova","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114996","article-title":"Current research status of anti-cancer peptides: mechanism of action, production, and clinical applications","volume":"164","author":"Chinnadurai","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0525","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.2147\/OTT.S207640","article-title":"In vitro mitochondrial-targeted antioxidant peptide induces apoptosis in cancer cells","volume":"12","author":"Zhan","year":"2019","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0530","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200004","article-title":"Anti-cancer peptides: classification, mechanism of action, reconstruction and modification","volume":"10","author":"Xie","year":"2020","journal-title":"Open Biol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0535","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17425247.2021.1860939","article-title":"Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine","volume":"18","author":"Kumar","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0540","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0545","doi-asserted-by":"crossref","first-page":"16131","DOI":"10.1039\/D1NR03502A","article-title":"Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D models","volume":"13","author":"Xu","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0550","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.apsb.2018.01.007","article-title":"Mesoporous silica nanoparticles for drug and gene delivery","volume":"8","author":"Zhou","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.773636","article-title":"Function and mechanism of RGD in bone and cartilage tissue engineering","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00898","article-title":"Preparation of RGD peptide\/folate acid double-targeted mesoporous silica nanoparticles and its application in human breast Cancer MCF-7 cells","volume":"11","author":"Yan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0565","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/pharmaceutics15010276","article-title":"Synergistic pro-apoptotic effect of a cyclic RGD peptide-conjugated magnetic mesoporous therapeutic Nanosystem on hepatocellular carcinoma HepG2 cells","volume":"15","author":"Zhao","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.803304","article-title":"Recent Progress of RGD modified liposomes as multistage rocket against Cancer","volume":"12","author":"Sheikh","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0575","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12964-021-00796-x","article-title":"Drug delivery strategy in hepatocellular carcinoma therapy","volume":"20","author":"Yang","year":"2022","journal-title":"Cell Commun. Signaling"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0580","first-page":"779","article-title":"Nanotechnology based approach for hepatocellular carcinoma targeting","volume":"22","author":"Alhalmi","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0585","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/s12951-024-03030-1","article-title":"Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma","volume":"22","author":"Babu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0590","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.3390\/jcm12216867","article-title":"Advances of nanotechnology in the diagnosis and treatment of hepatocellular carcinoma","volume":"12","author":"Escutia-Guti\u00e9rrez","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0595","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/IJN.S236927","article-title":"Nanocarrier-based therapeutics and Theranostics drug delivery Systems for Next Generation of liver Cancer Nanodrug modalities","volume":"15","author":"Ruman","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12672-025-01821-y","article-title":"Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review","volume":"16","author":"Bhange","year":"2025","journal-title":"Discover Oncology"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0605","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0610","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12951-025-03512-w","article-title":"Advancing liver cancer treatment with dual-targeting CAR-T therapy","volume":"23","author":"Yang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0615","first-page":"256","article-title":"PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and Sorafenib in patients with advanced hepatocellular carcinoma, liver","volume":"13","author":"Abou-Alfa","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0620","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4103\/jcrt.JCRT_801_18","article-title":"Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: a randomized, double-blinded, dummy-controlled clinical trial in a single cent","volume":"15","author":"Yang","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0625","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1078-0432.CCR-16-2433","article-title":"Phase III HEAT study adding Lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with Unresectable hepatocellular carcinoma lesions","volume":"24","author":"Tak","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0630","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.7150\/thno.54822","article-title":"Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma","volume":"11","author":"Kong","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0635","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/bios12050342","article-title":"Targeted molecular imaging probes based on magnetic resonance imaging for hepatocellular carcinoma diagnosis and treatment","volume":"12","author":"Zhao","year":"2022","journal-title":"Biosensors"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0640","article-title":"From conventional therapy to treatment with lipid-polymer hybrid nanoparticles for hepatocellular carcinoma","volume":"47","author":"Farinha","year":"2025","journal-title":"Mater. Today Chem."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0645","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0650","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.3390\/jcm11164874","article-title":"The combining of tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for advanced stage hepatocellular carcinoma","volume":"11","author":"Lee","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1205636","article-title":"Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0660","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202105179","article-title":"A bionic-homodimerization strategy for optimizing modulators of protein\u2013protein interactions: from statistical mechanics theory to potential clinical translation","volume":"9","author":"Yan","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113995","article-title":"Synthetic polypeptides for drug and gene delivery, and tissue engineering","volume":"178","author":"Yin","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0670","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.7150\/thno.83377","article-title":"Targeting \u03b2-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma","volume":"13","author":"Zhou","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0675","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2147\/JHC.S390963","article-title":"Immune-based combination therapies for advanced hepatocellular carcinoma","volume":"10","author":"Carloni","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0680","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.trecan.2020.12.012","article-title":"Targeting cancer heterogeneity with immune responses driven by oncolytic peptides","volume":"7","author":"Vitale","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0685","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1039\/D0NP00019A","article-title":"Cytotoxic and antitumor peptides as novel chemotherapeutics","volume":"38","author":"Luan","year":"2021","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0690","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D0CS00556H","article-title":"Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs)","volume":"50","author":"Cooper","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114354","article-title":"MOTS-c relieves hepatocellular carcinoma resistance to TRAIL-induced apoptosis under hypoxic conditions by activating MEF2A","volume":"444","author":"Shen","year":"2025","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12249-024-03011-5","article-title":"From bench to bedside: ROS-responsive nanocarriers in cancer therapy","volume":"26","author":"Chauhan","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0705","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1152\/physrev.00039.2012","article-title":"Physiology and pathophysiology of carnosine","volume":"93","author":"Boldyrev","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150512_bb0710","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.62347\/QLHG1014","article-title":"Protective effect of N-acetylcysteine against hepatocellular carcinoma in hepatitis B virus carriers","volume":"14","author":"Wu","year":"2024","journal-title":"Am. J. Cancer Res."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026004381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026004381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:17:28Z","timestamp":1770052648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026004381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":142,"alternative-id":["S0141813026004381"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150512","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150512"}}